Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Janus Kinase (JAK) Inhibitors in CTCL: Friend or Foe?
Description
Dr. Oris Hewen, an associate professor at MD Anderson, discusses the role of Janus Kinase (JAK) inhibitors in treating cutaneous T cell lymphoma (CTCL). She explains the JAK-STAT signaling pathway and the impact of JAK inhibitors in dampening T cell growth and function by blocking STAT phosphorylation. Various JAK inhibitors, such as Galito Sittin and Rexalitin, are explored in clinical trials, with preliminary results showing promise, especially in advanced stages of lymphoma. However, concerns arise regarding the potential for JAK inhibitors to exacerbate existing lymphomas or trigger new ones, particularly in immunocompromised patients. Case studies reveal instances of lymphoproliferative disorders and relapsed disease in patients treated with JAK inhibitors. The data are inconclusive, necessitating careful patient selection and monitoring. Additionally, effective combinations with immunotherapy and other treatments are highlighted, stressing the importance of understanding the heterogeneous nature of CTCL and its varying cytokine profiles. Dr. Hewen emphasizes the need for further research to identify which subgroups of patients could benefit from JAK inhibitors while considering the risks associated with their use.
View moreConclusions
- Jack inhibitors show promise in the treatment of cutaneous T-cell lymphoma (CTCL) with variable response rates among different subtypes.
- Cytokine profiles change as CTCL progresses, influencing the effectiveness of Jack inhibitors.
- The presence of certain mutations, such as JAK2 and JAK3, is linked to the pathogenesis and progression of CTCL.
- Immune suppression caused by Jack inhibitors can potentially lead to disease progression in CTCL patients.
- Evaluating the risk of Jack inhibitors causing or exacerbating CTCL in patients is crucial, particularly in post-transplant settings.
- Further formal investigations are needed to assess which subgroups of patients may benefit from Jack inhibitor therapies and under which circumstances.
- The choice between oral and topical formulations of Jack inhibitors may affect treatment outcomes, particularly in early versus advanced stages of CTCL.
- Continued exploration of ideal Jack inhibitor selection is necessary to optimize treatment efficacy and minimize adverse effects.
- Sardana et al. Expert Rev Clin Pharmacol. 2023 Apr;16(4):279-295.
- Virtanen et al. Nat Rev Rheumatol. 2024 Oct;20(10):649-665
- Yumeen et al. Blood Adv. 2020 May 26;4(10):2213-2226
- Ni et al. Cancers 2025, 17(4), 568
- Karagianni et al. PLoS ONE 2021, 16, e0248298.
- Chen et al. Int. Immunopharmacol. 2024, 130, 111717.
- Porpaczy et al. Blood. 2018 Aug 16;132(7):694-706.
- Pemmaraju et al. Blood. 2019 May 23;133(21):2348-2351.